

[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
[ Fri, Mar 01st 2024
] - WOPRAI
Tessa Romero Maintained (ACAD) at Buy with Decreased Target to $29 on, Mar 1st, 2024
Tessa Romero of JP Morgan, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $32 to $29 on, Mar 1st, 2024.
Tessa has made no other calls on ACAD in the last 4 months.
There are 14 other peers that have a rating on ACAD. Out of the 14 peers that are also analyzing ACAD, 3 agree with Tessa's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jay Olson of "Oppenheimer" Reiterated at Hold and Held Target at $25 on, Monday, February 5th, 2024
- Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $27 on, Monday, December 18th, 2023
- Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023
These are the ratings of the 11 analyists that currently disagree with Tessa
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $36 on, Wednesday, February 28th, 2024
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $33 on, Wednesday, February 28th, 2024
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $42 on, Wednesday, February 28th, 2024
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $35 on, Wednesday, February 28th, 2024
- Uy Ear of "Mizuho" Maintained at Strong Buy with Decreased Target to $39 on, Wednesday, February 28th, 2024
- Jason Butler of "JMP Securities" Reiterated at Buy and Held Target at $42 on, Wednesday, February 7th, 2024
- Joel Beatty of "Baird" Initiated at Buy and Held Target at $40 on, Tuesday, January 30th, 2024
- Joseph Stringer of "Needham" Upgraded from Hold to Strong Buy and Held Target at $37 on, Wednesday, January 24th, 2024
- Jeffrey Hung of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $40 on, Tuesday, December 19th, 2023
- David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $38 on, Wednesday, December 13th, 2023
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, November 6th, 2023
Contributing Sources